Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Hidradenitis suppurativa staging and care

Dermatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Do not label spreading infection as an ordinary flare

Rapidly spreading erythema or colour change, disproportionate pain, crepitus, systemic toxicity or perineal necrosis suggests cellulitis, sepsis or necrotising infection beyond uncomplicated hidradenitis.

Action: Assess ABCDE, start the local sepsis pathway, obtain urgent surgical review for possible necrotising infection and give antimicrobials without delaying source control.

Synopsis

Diagnose hidradenitis suppurativa from recurrent lesions in typical flexures, stage structural damage, identify emergencies and comorbidity, and coordinate medical, wound, pain, lifestyle and surgical care without blame.

  • Diagnosis rests on typical lesions, typical flexural sites and chronic recurrence: painful nodules, abscesses, tunnels and scars in axillae, groins, inframammary, abdominal-fold, genital, perianal or buttock skin.
  • Ask whether there have been at least two episodes in six months, but do not let an arbitrary frequency erase a convincing longer recurrent history.
  • Hurley I has nodules or abscesses without tunnels and permanent scars; Hurley II has recurrent lesions with separated tunnels or scars; Hurley III has diffuse interconnected disease.
  • Hurley stage records structural damage, not today’s inflammatory activity, pain or quality of life; include active lesion counts and patient priorities separately.
  • Hidradenitis is not caused by poor hygiene and is not contagious; use non-stigmatising language when discussing smoking, weight and friction as modifiable associations.
  • Routine swabbing is unnecessary for a typical inflammatory flare; culture fresh pus when secondary infection, unusual organisms or repeated antibiotic failure is suspected.
  • Medical treatment can suppress new inflammation, but persistent tunnels and scarred fields often need deroofing or excision for durable local control.
  • Screen for depression, pain, metabolic and cardiovascular risk, inflammatory bowel symptoms and inflammatory joint disease, and ask about sexual and work impact.

Key red flags

Sepsis physiology, rapidly progressive perineal pain, crepitus, urinary obstruction, uncontrolled bleeding, a chronic ulcer or mass suggesting squamous-cell carcinoma, severe depression or suicidal thoughts requires urgent escalation.

Necrotising-infection warning

Rapid perineal progression, disproportionate pain, crepitus, dusky necrosis, confusion or hypotension requires immediate surgical and sepsis management.

Carcinoma warning change

A new hard mass, persistent ulcer, bleeding or altered pain in long-standing anogenital disease needs urgent biopsy and specialist review.

Investigation priorities

01
Full-site lesion map and Hurley stageFirst step

Document structural extent and identify areas needing medical or procedural treatment.

Management branches

Limited early diseaseReduce new inflammatory lesions

Hurley I or limited Hurley II disease has active nodules without an emergency or extensive tunnel field.

  1. Explain the diagnosis without hygiene blame, reduce friction and traumatic hair removal, offer absorbent non-adherent dressings and create a proportionate pain plan.
  2. Consider off-label topical clindamycin for localised disease or a twelve-week oral tetracycline for more widespread activity, using an explicit response and stop assessment.
  3. Review recurrence, adverse effects, tunnels and scars; escalate early if new structural damage develops rather than repeating acute abscess prescriptions.

Key medicines

Clindamycin 1% topical lotionApply a thin film twice daily to clean, dry affected areas for a defined trial according to the agreed off-label hidradenitis plan.Avoid indefinite exposure, consider previous antibiotic resistance and colitis, stop for significant diarrhoea or irritation, and do not apply deeply into open cavities.
Lymecycline 408 mg capsulesTake one capsule orally once daily for an initial twelve-week off-label anti-inflammatory course, with a documented response and stop review.Avoid pregnancy, breastfeeding and under 12 years; consider photosensitivity, organ impairment, absorption interactions and intracranial-pressure symptoms, and do not combine with isotretinoin.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • British Association of Dermatologists hidradenitis suppurativaCurrent recognition, causes, comorbidity, medical and surgical care.
  • NHS hidradenitis suppurativaUK diagnosis, flare care, treatment and patient support.
  • NICE TA392 Adalimumab for hidradenitis suppurativaNHS eligibility and precise twelve-week continuation criteria.
  • Dalacin T topical lotion SmPCClindamycin topical strength, application and adverse effects, used off label in hidradenitis.
  • Tetralysal 300 mg capsules SmPCLymecycline dose form and safety for the off-label inflammatory regimen.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom